Priothera
priothera.com
Actively hiring
Financial Services
Biotechnology
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Team
6–9
French register · Dec 2023
Revenue
$20.5M
2024 · French register
Backers
1
HealthCap
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
2019
Founded
Registers and programsofficial lists and records that name the company
| Legal entity | PRIOTHERA SAS | its site |
| Registered | 30 Sep 2020 |
Backed byfrom the funds' portfolios and accelerator catalogs
HealthCap Similar startupsby what they do, their industry and backers
DoMore Diagnostics is on a mission to transform cancer diagnostics with artificial intelligence to improve patient care and make drug…
Developing novel treatments for patients with atrial fibrillation. We are developing drugs designed to safety, effectively, and quickly get…
Abinitio bio is the AI-native operating platform for drug development and manufacturing.
About us. Our Leadership team is composed of seasoned professionals with a strong expertise in the orphan diseases and gene therapy field.
About Mission Leadership Life & Culture Businesses Product Integrity Cincinnati Test Systems, Inc.
About us We are on a mission We empower oncology professionals with the most advanced technologies to help them deliver high-quality…
Overview
Our Leadership Team Our founders are globally acknowledged scientists and drug development leaders whose vision is to make a difference in AML patient care. Leadership Team Mr.
News
Priothera Appoints Experienced Biotech Executive, Dr Nigel Clark, as Chief Business Officer to Lead Strategic Partnering for Mocravimod
Saint-Louis, France and Dublin, Ireland - 3rd June 2025 - Priothera Ltd., a late-stage biopharma company pioneering the development of mocravimod, a novel oral sphingosine 1 phosphate (S1P) receptor modulator, to treat hematologic malignancies, today anno
Read more
Report
Priothera Appoints Experienced Biotech Executive, Dr Nigel Clark, as Chief Business Officer to Lead Strategic Partnering for Mocravimod
Priothera is the only company in advanced clinical development with a potential maintenance treatment for patients with acute myeloid leukaemia un...
Read more
Report
Priothera Appoints Experienced Biotech Executive, Dr Nigel Clark, as Chief Business Officer to Lead Strategic Partnering for Mocravimod
Priothera is the only company in advanced clinical development with a potential maintenance treatment for patients with acute myeloid leukaemia undergoing allogeneic hematopoietic cell transplantation Saint-Louis, France and Dublin, Ireland - 3 September
Read more
Report
Clinical assessment of mocravimod as a victim of drug-drug interactions via CYP3A4 metabolism and transporters
Mocravimod, a novel immunomodulator targeting sphingosine-1-phosphate receptor (S1PR), is being developed as a maintenance treatment for patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.
Read more
Report
Priothera accélère sur son traitement des cancers hématologiques
A report to provide an update on the development of our drug candidate, mocravimod, currently in a phase 3 clinical trial for the treatment of acute myeloid leukemia (AML). View the video.
Read more
Report
Pro access
Upgrade to see all 18 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Mulhouse
France
Registered seat
50-200 est. staff
Financials
Est. Annual Revenue
$20.5M
2024